132 related articles for article (PubMed ID: 6584388)
1. Chemosensitivity testing of nonsolid tumors by the subrenal-capsule implant assay.
Stratton JA; Micha JP; Rettenmaier MA; Braley PS; DiSaia PJ
Gynecol Oncol; 1984 Feb; 17(2):185-8. PubMed ID: 6584388
[TBL] [Abstract][Full Text] [Related]
2. [Fundamental studies on the subrenal capsule assay as chemosensitivity test for nonsolid tumors].
Sakamoto T; Ogino M; Yamamoto T; Mori H; Okinaga S; Arai K
Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):415-21. PubMed ID: 2197356
[TBL] [Abstract][Full Text] [Related]
3. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
4. Ultrastructural effects of alpha and gamma interferons and cytostatics on ovarian cancer cells in the subrenal capsule assay (SRCA).
Söderström KO; Mäenpää J; Cantell K; Kangas L; Grönroos M
Ann Chir Gynaecol Suppl; 1985; 199():38-43. PubMed ID: 3933399
[TBL] [Abstract][Full Text] [Related]
5. Accurate prediction of experimental cancer chemosensitivity using the subrenal capsule xenograft assay.
Bennett JA; Pilon VA; Uppal GS; McKneally MF
J Surg Oncol; 1986 Sep; 33(1):8-13. PubMed ID: 3762179
[TBL] [Abstract][Full Text] [Related]
6. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
7. Concordance of combination and single agent chemosensitivity prediction in ovarian carcinoma using the subrenal capsule xenograft assay (SRCA).
Stratton JA; Rettenmaier MA; Kucera PR; Berman ML; DiSaia PJ
Gynecol Oncol; 1988 Jul; 30(3):416-21. PubMed ID: 3391423
[TBL] [Abstract][Full Text] [Related]
8. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
[TBL] [Abstract][Full Text] [Related]
9. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
10. [In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay].
Nishiyama M; Niimi K; Yamaguchi M; Hirabayashi N; Nosoh Y; Tohge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):109-13. PubMed ID: 3099648
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
Piver MS; Malfetano J; Baker TR; Lele SB; Marchetti DL
Gynecol Oncol; 1989 Oct; 35(1):69-72. PubMed ID: 2792905
[TBL] [Abstract][Full Text] [Related]
12. Subrenal capsule assay in choosing cytostatics for gynaecological tumours.
Mäenpää J; Grönroos M; Kangas L
Ann Chir Gynaecol Suppl; 1985; 199():28-30. PubMed ID: 3864390
[TBL] [Abstract][Full Text] [Related]
13. Malignant pericardial effusion in ovarian carcinoma cured by systemic chemotherapy.
Mäenpää J; Taina E; Erkkola R
Gynecol Oncol; 1988 Jun; 30(2):298-301. PubMed ID: 3371750
[TBL] [Abstract][Full Text] [Related]
14. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
[TBL] [Abstract][Full Text] [Related]
15. Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer.
Suonio E; Lipponen P; Mäenpää J; Syrjänen K; Kangas L; Tuomisto L
Cancer Chemother Pharmacol; 1997; 41(1):15-21. PubMed ID: 9443609
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay.
Stratton JA; Mannel RS; Rettenmaier MA; Berman ML; DiSaia PJ
Gynecol Oncol; 1989 Jan; 32(1):55-9. PubMed ID: 2535831
[TBL] [Abstract][Full Text] [Related]
17. [Clinical application of subrenal capsule assay in ovarian cancer].
Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
[TBL] [Abstract][Full Text] [Related]
18. [Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
Wang Y; Inoue K; Shibata H; Itoh Y; Chen SC; Ogawa M
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1264-7. PubMed ID: 3579325
[TBL] [Abstract][Full Text] [Related]
19. [Subrenal capsule assay for chemosensitivity testing].
Kusuyama T; Fujita M; Shimozuma K; Orikasa H; Usugane M; Taguchi T
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1143-9. PubMed ID: 3105468
[TBL] [Abstract][Full Text] [Related]
20. The subrenal capsule tumor implant assay as a predictor of clinical response to chemotherapy: 3 years of experience.
Stratton JA; Kucera PR; Micha JP; Rettenmaier MA; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1984 Nov; 19(3):336-47. PubMed ID: 6500376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
